Alteplase for stroke: money and optimistic claims buttress the "brain attack" campaign.
作者信息
Lenzer Jeanne
机构信息
Oak Ridge Journalism, Ellenville, NY 12428, USA.
出版信息
BMJ. 2002 Mar 23;324(7339):723-9. doi: 10.1136/bmj.324.7339.723.
Abstract
摘要
相似文献
1
Alteplase for stroke: money and optimistic claims buttress the "brain attack" campaign.用于治疗中风的阿替普酶：金钱与乐观的宣称支撑着“脑部发作”宣传活动。
BMJ. 2002 Mar 23;324(7339):723-9. doi: 10.1136/bmj.324.7339.723.
2
Controversial stroke trial is under review following BMJ report.在《英国医学杂志》发布报告后，备受争议的中风试验正在接受审查。
BMJ. 2002 Nov 16;325(7373):1131. doi: 10.1136/bmj.325.7373.1131.
3
Alteplase for stroke. American Heart Association explains how guidelines were formulated.用于治疗中风的阿替普酶。美国心脏协会解释指南制定过程。
BMJ. 2002 Jun 29;324(7353):1581; author reply 1581.
4
IV tissue plasminogen activator for stroke in the community: what we know and don't know 10 years after FDA approval.静脉注射组织型纤溶酶原激活剂用于社区中风治疗：FDA批准十年后的知与未知
Stroke. 2006 Feb;37(2):281. doi: 10.1161/01.STR.0000199853.52386.70. Epub 2006 Jan 5.
5
Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association.静脉注射阿替普酶用于急性缺血性脑卒中的纳入和排除标准的科学依据：美国心脏协会/美国卒中协会医疗保健专业人员的声明。
Stroke. 2016 Feb;47(2):581-641. doi: 10.1161/STR.0000000000000086. Epub 2015 Dec 22.
6
EMS mythology. EMS myth #2. Thombolytic therapy is the standard of care for acute ischemic stroke.急救医疗服务的神话。急救医疗服务神话之二。溶栓治疗是急性缺血性中风的护理标准。
Emerg Med Serv. 2003 Apr;32(4):63-5.
7
Doubts, fears and misconceptions. What is the future of thrombolysis in acute stroke?疑虑、恐惧与误解。急性卒中溶栓治疗的未来走向何方？
Can J Neurol Sci. 2000 Nov;27(4):283-7. doi: 10.1017/s0317167100001001.
8
Reasons for exclusion from thrombolytic therapy following acute ischemic stroke.急性缺血性卒中后溶栓治疗排除标准
Neurology. 2005 Dec 13;65(11):1844; author reply 1844. doi: 10.1212/01.wnl.0000200031.41939.ac.
9
Optimal timing of thrombolytic therapy in acute ischaemic stroke.急性缺血性卒中溶栓治疗的最佳时机
CNS Drugs. 2002;16(4):213-8. doi: 10.2165/00023210-200216040-00001.
10
4.5 hours: the new time window for tissue plasminogen activator in stroke.4.5小时：中风患者使用组织纤溶酶原激活剂的新时间窗。
Stroke. 2009 Jun;40(6):2266-7. doi: 10.1161/STROKEAHA.108.544171. Epub 2009 Apr 30.
引用本文的文献
1
Fifty Years of Acute Ischemic Stroke Treatment: A Personal History.《急性缺血性脑卒中治疗的五十年：个人史》
Cerebrovasc Dis. 2021;50(6):666-680. doi: 10.1159/000519843. Epub 2021 Oct 14.
2
Thrombolysis with alteplase 3-4.5 hours after acute ischaemic stroke: trial reanalysis adjusted for baseline imbalances.阿替普酶溶栓治疗急性缺血性脑卒中 3-4.5 小时：调整基线失衡的试验重新分析。
BMJ Evid Based Med. 2020 Oct;25(5):168-171. doi: 10.1136/bmjebm-2020-111386. Epub 2020 May 19.
3
tPA for Acute Ischemic Stroke and Its Controversies: A Review.急性缺血性卒中的组织型纤溶酶原激活剂及其争议：综述
Neurohospitalist. 2020 Jan;10(1):5-10. doi: 10.1177/1941874419838961. Epub 2019 Apr 14.
4
Thrombolytic Treatment for Ischaemic Stroke: Could the Crisis of Confidence Have Been Avoided by Better Analysis of Trial Data?缺血性中风的溶栓治疗：通过对试验数据进行更好的分析能否避免信任危机？
Drugs Aging. 2017 Feb;34(2):79-88. doi: 10.1007/s40266-016-0432-8.
5
Conflict of interest disclosure in biomedical research: A review of current practices, biases, and the role of public registries in improving transparency.生物医学研究中的利益冲突披露：当前实践、偏见以及公共注册机构在提高透明度方面的作用综述
Res Integr Peer Rev. 2016;1. doi: 10.1186/s41073-016-0006-7. Epub 2016 May 3.
6
Why don't more patients receive intravenous rt-PA for acute stroke?为什么更多的急性中风患者没有接受静脉注射重组组织型纤溶酶原激活剂（rt-PA）治疗？
Expert Rev Neurother. 2015 Jun;15(6):571-4. doi: 10.1586/14737175.2015.1041510. Epub 2015 May 4.
7
Thrombolysis for acute ischaemic stroke.急性缺血性卒中的溶栓治疗
Cochrane Database Syst Rev. 2014 Jul 29;2014(7):CD000213. doi: 10.1002/14651858.CD000213.pub3.
8
Pharmaceutical sponsorship bias influences thrombolytic literature in acute ischemic stroke.制药公司赞助会影响急性缺血性脑卒中溶栓文献。
West J Emerg Med. 2011 Nov;12(4):435-41. doi: 10.5811/westjem.2011.5.2166.
9
Concerned Journals, Editors And ICMJE.相关期刊、编辑和国际医学期刊编辑委员会
Mens Sana Monogr. 2007 Jan;5(1):90-107. doi: 10.4103/0973-1229.32152.
10
Foundations and task forces.基金会与特别工作组。
Mens Sana Monogr. 2007 Jan;5(1):79-89. doi: 10.4103/0973-1229.32151.
本文引用的文献
1
Evidence of publication bias in reporting acute stroke clinical trials.急性中风临床试验报告中发表偏倚的证据。
Neurology. 2006 Sep 26;67(6):973-9. doi: 10.1212/01.wnl.0000237331.16541.ac.
2
Relationships between authors of clinical practice guidelines and the pharmaceutical industry.临床实践指南作者与制药行业之间的关系。
JAMA. 2002 Feb 6;287(5):612-7. doi: 10.1001/jama.287.5.612.
3
ATLANTIS trial: results for patients treated within 3 hours of stroke onset. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.亚特兰蒂斯试验：卒中发作3小时内接受治疗患者的结果。急性缺血性卒中阿替普酶溶栓非介入治疗
Stroke. 2002 Feb;33(2):493-5. doi: 10.1161/hs0202.102599.
4
Number needed to treat (NNT): estimation of a measure of clinical benefit.需治疗人数（NNT）：临床获益衡量指标的估计值。
Stat Med. 2001 Dec 30;20(24):3947-62. doi: 10.1002/sim.1173.
5
Improving delivery of acute stroke therapy: The TLL Temple Foundation Stroke Project.改善急性中风治疗的提供：TLL 坦普尔基金会中风项目。
Stroke. 2002 Jan;33(1):160-6. doi: 10.1161/hs0102.101990.
6
Extending tissue plasminogen activator use to community and rural stroke patients.将组织纤溶酶原激活剂的应用扩展至社区及农村中风患者。
Stroke. 2002 Jan;33(1):141-6. doi: 10.1161/hs0102.100481.
7
Industry-sponsored clinical research: a double-edged sword.行业资助的临床研究：一把双刃剑。
Lancet. 2001 Dec 1;358(9296):1893-5. doi: 10.1016/S0140-6736(01)06891-X.
8
Annals supplement on the American Heart Association proceedings.《美国心脏协会会议纪要》增刊
Ann Emerg Med. 2001 Nov;38(5):605. doi: 10.1067/mem.2001.119276.
9
Sponsorship, authorship, and accountability.赞助、作者身份与责任。
Lancet. 2001 Sep 15;358(9285):854-6. doi: 10.1016/s0140-6736(01)06035-4.
10
Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study.早期卒中治疗与更好的预后相关：美国国立神经疾病与卒中研究所rt-PA卒中研究
Neurology. 2000 Dec 12;55(11):1649-55. doi: 10.1212/wnl.55.11.1649.
Zotero 插件